Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Research & Drug Development
Therapeutic Focus
Newron has built a CNS-focused pipeline that embodies highly innovative compounds at a variety of development phases. Safinamide, partnered with Merck Serono, is in late stage Phase III trials; all other compounds are being developed by Newron and will progress in new partnerships with other companies at various stages.